PRTA Prothena Corp Public Ltd Co

  1. Stocks
  2. Healthcare
  3. NASDAQ: PRTA

Price (delayed)

$21.16

Market cap

$1.14B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2.76

Enterprise value

$528.38M

Prothena Corporation plc is a late-stage clinical company with expertise in protein dysregulation and a diverse pipeline of novel investigational therapeutics with the potential to change the course of devastating ...

Highlights
Prothena's revenue has soared by 70% YoY but it has decreased by 35% from the previous quarter
The company's gross profit has surged by 70% YoY but it fell by 35% QoQ
The company's EPS has shrunk by 104% QoQ and by 12% YoY
The net income has plunged by 101% from the previous quarter and by 26% YoY
Sector: Healthcare
Industry: Biotechnology
Website: http://www.prothena.com/
Peers: ALKS ALNY AMRN

Key stats

What are the main financial stats of PRTA
Market
Shares outstanding
53.72M
Market cap
$1.14B
Enterprise value
$528.38M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
2.02
Price to sales (P/S)
12.32
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
5.78
Earnings
Revenue
$91.37M
EBIT
-$160.48M
EBITDA
-$152.07M
Free cash flow
-$136.68M
Per share
EPS
-$2.76
Free cash flow per share
-$2.57
Book value per share
$10.46
Revenue per share
$1.72
TBVPS
$13.09
Balance sheet
Total assets
$696.38M
Total liabilities
$135.02M
Debt
$11.84M
Equity
$561.37M
Working capital
$582.39M
Liquidity
Debt to equity
0.02
Current ratio
11.24
Quick ratio
10.99
Net debt/EBITDA
4
Margins
EBITDA margin
-166.4%
Gross margin
100%
Net margin
-160.9%
Operating margin
-209.1%
Efficiency
Return on assets
-20.2%
Return on equity
-24.8%
Return on invested capital
-963.1%
Return on capital employed
-25.1%
Return on sales
-175.6%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

PRTA stock price

How has the Prothena stock price performed over time
Intraday
2.87%
1 week
-4.86%
1 month
-15.66%
1 year
-60.18%
YTD
-41.77%
QTD
-14.57%

Financial performance

How have Prothena's revenue and profit performed over time
Revenue
$91.37M
Gross profit
$91.37M
Operating income
-$191.04M
Net income
-$147.03M
Gross margin
100%
Net margin
-160.9%
The operating margin has dropped by 162% since the previous quarter but it is up by 14% year-on-year
The net income has plunged by 101% from the previous quarter and by 26% YoY
Prothena's revenue has soared by 70% YoY but it has decreased by 35% from the previous quarter
The company's gross profit has surged by 70% YoY but it fell by 35% QoQ

Growth

What is Prothena's growth rate over time

Valuation

What is Prothena stock price valuation
P/E
N/A
P/B
2.02
P/S
12.32
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
5.78
The company's EPS has shrunk by 104% QoQ and by 12% YoY
PRTA's price to book (P/B) is 55% lower than its last 4 quarters average of 4.5 and 47% lower than its 5-year quarterly average of 3.8
The company's equity fell by 10% YoY and by 9% QoQ
PRTA's price to sales (P/S) is 96% lower than its 5-year quarterly average of 309.8 and 67% lower than its last 4 quarters average of 37.2
Prothena's revenue has soared by 70% YoY but it has decreased by 35% from the previous quarter

Efficiency

How efficient is Prothena business performance
The company's return on sales has shrunk by 186% QoQ but it rose by 25% YoY
The ROE has plunged by 105% from the previous quarter
Prothena's return on assets has shrunk by 104% QoQ and by 6% YoY
The ROIC has grown by 17% YoY but it has contracted by 10% from the previous quarter

Dividends

What is PRTA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for PRTA.

Financial health

How did Prothena financials performed over time
PRTA's current ratio is down by 22% year-on-year and by 13% since the previous quarter
The quick ratio has declined by 22% year-on-year and by 13% since the previous quarter
Prothena's debt is 98% less than its equity
Prothena's debt to equity has surged by 100% YoY
Prothena's debt has soared by 83% YoY and by 10% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.